Related Experiment Video
Updated: Sep 5, 2025

06:52
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.4K
The Periodontal Pathogen Fusobacterium nucleatum Exacerbates Alzheimer's Pathogenesis via Specific Pathways
Hongle Wu1,2,3, Wei Qiu4, Xiaofang Zhu3,5
1Department of Endodontics, Stomatological Hospital, Southern Medical University, Guangzhou, China.
Frontiers in Aging Neuroscience
|July 11, 2022
Summary
This study links the oral bacterium Fusobacterium nucleatum to Alzheimer's disease (AD). F. nucleatum infection exacerbates AD symptoms in mice, suggesting it may be a risk factor for the neurodegenerative disease.
Area of Science:
- Neuroscience
- Microbiology
- Oral Health
Background:
- Alzheimer's Disease (AD) is a leading cause of dementia with significant societal impact.
- Periodontitis, an oral inflammatory disease, has been increasingly linked to AD.
- Fusobacterium nucleatum, a key pathogen in periodontitis, has been detected in AD patients, but a causal link remains unclear.
Purpose of the Study:
- To investigate the causal relationship and underlying mechanisms between Fusobacterium nucleatum infection and Alzheimer's Disease pathogenesis.
- To determine if F. nucleatum can activate microglial cells and exacerbate AD symptoms in a mouse model.
Main Methods:
- In vitro experiments assessed F. nucleatum's effect on microglial cell activation, proliferation, and inflammatory marker expression (TNF-α, IL-1β).
- In vivo studies utilized 5XFAD mice with induced periodontitis to evaluate cognitive impairment, beta-amyloid deposition, and Tau phosphorylation.
- Proteomic data is available via ProteomeXchange (identifier PXD033147).
Main Results:
- F. nucleatum significantly activated microglial cells, causing morphological changes and increased TNF-α and IL-1β expression.
- Infected mice exhibited worsened cognitive deficits, elevated beta-amyloid accumulation, and increased Tau phosphorylation in the brain.
- These findings demonstrate a direct link between F. nucleatum infection and exacerbated AD pathology.
Conclusions:
- Fusobacterium nucleatum may act as a risk factor contributing to the pathogenesis of Alzheimer's Disease.
- The study provides evidence for a potential mechanism linking periodontal disease to neurodegeneration.
- Further research is ongoing to elucidate the specific molecular pathways involved.
Related Concept Videos
Alzheimer's Disease: Overview
663
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
663
Amyloid Fibrils
9.8K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.8K
Alzheimer's Disease: Treatment
259
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
259

